SCHEMBL2591393

SCHEMBL2591393

[2H]C([2H])Oc1c(OC)ccc(-c2cccc3c2CCC3=O)c1OCC1(C(=O)OC(C)C)CC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
PDE4D Q08499 2/20 0.32
S1PR1 P21453 1/20 0.32
HDAC4 P56524 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
MEN1 O00255 1/20 0.31
USP2 O75604 1/20 0.31
S100A4 P26447 1/20 0.31
KMT2A Q03164 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ABCB1 P08183 2/20 0.31
GAA P10253 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14737529 0.97 ALDH1A1 (0.36) ALDH1A1KDM4EHPGDS1PR1ABCB1
SCHEMBL2591999 0.97 KDM4E (0.39) ALDH1A1KDM4EHPGDPDE4DS1PR1
SCHEMBL2591568 0.96 ALDH1A1 (0.40) ALDH1A1KDM4EHPGDPDE4DS1PR1
SCHEMBL2588130 0.95 ALDH1A1 (0.40) ALDH1A1KDM4EHPGDPDE4DS1PR1
SCHEMBL14738179 0.95 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDPDE4DS1PR1
SCHEMBL14737666 0.94 ALDH1A1 (0.35) ALDH1A1KDM4EHPGDS1PR1ABCB1
SCHEMBL2591423 0.93 KDM4E (0.39) ALDH1A1KDM4EHPGDS1PR1HDAC4
SCHEMBL2585737 0.93 ALDH1A1 (0.40) ALDH1A1KDM4EHPGDPDE4DS1PR1
SCHEMBL14738697 0.92 ALDH1A1 (0.36) ALDH1A1KDM4EHPGDS1PR1ABCB1
SCHEMBL2591883 0.91 KDM4E (0.39) ALDH1A1KDM4EHPGDPDE4DHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
EP-2563770-A1 BIARYL PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2013-03-06 EP disclosed
WO-2011134468-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2011-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A ALDH1A1 824/4885KDM4E 1593/4885HPGD 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.